Pictet Asset Management Holding SA Has $73.45 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Pictet Asset Management Holding SA boosted its holdings in Moderna, Inc. (NASDAQ:MRNA) by 170.5% during the fourth quarter, HoldingsChannel.com reports. The fund owned 1,766,398 shares of the company’s stock after purchasing an additional 1,113,455 shares during the period. Pictet Asset Management Holding SA’s holdings in Moderna were worth $73,447,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in MRNA. Cerity Partners LLC raised its holdings in shares of Moderna by 7.0% in the third quarter. Cerity Partners LLC now owns 13,769 shares of the company’s stock valued at $920,000 after buying an additional 900 shares during the last quarter. Larson Financial Group LLC raised its position in Moderna by 53.5% in the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after purchasing an additional 317 shares during the last quarter. Fisher Asset Management LLC acquired a new position in Moderna during the 3rd quarter worth $419,000. D.A. Davidson & CO. boosted its position in Moderna by 16.2% in the 3rd quarter. D.A. Davidson & CO. now owns 39,937 shares of the company’s stock valued at $2,669,000 after buying an additional 5,565 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Moderna in the 3rd quarter valued at $150,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Price Performance

Shares of Moderna stock opened at $31.12 on Friday. The company has a market capitalization of $12.03 billion, a P/E ratio of -3.35 and a beta of 1.86. The business has a 50-day moving average of $34.72 and a two-hundred day moving average of $44.38. Moderna, Inc. has a 1 year low of $29.25 and a 1 year high of $170.47.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on MRNA. Berenberg Bank upped their price target on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research note on Thursday, January 16th. JPMorgan Chase & Co. cut their target price on shares of Moderna from $40.00 to $33.00 and set an “underweight” rating on the stock in a research report on Friday, March 21st. Leerink Partners lowered their price target on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research report on Thursday, January 16th. Citigroup started coverage on shares of Moderna in a report on Thursday, March 13th. They issued a “neutral” rating and a $40.00 price objective on the stock. Finally, Bank of America lowered their target price on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a report on Tuesday, February 11th. Four investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $59.00.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.